GSK respond to negative NICE recommendation on Tykerb

GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. The company says “we strongly believe that the wrong decision has been made for patients, doctors and the NHS”

Abbott publish series of EGFR/ ErbB-2 inhibitor

Abbott have published a series of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidine EGFR/ ErbB-2 Inhibitors.

GSKs Tykerb (lapatinib) effective in advanced head and neck cancer

Phase II data presented at the European of Medical Oncology (ESMO) show that GSK’s Tykerb (lapatinib) is effective in advanced head and neck cancer

Combination of a sheddase inhibitor INCB3619 with lapatinib improves anti-tumor effect

Researchers have shown that the addition of sheddase inhibitor INCB3619 to lapatinib treated cells increases antitumor activity

BMS ready to initiate Phase II trial of BMS-690514 in NSCLC

BMS are preparing to initiate a Phase II trial of pan-HER inhibitor BMS-690514 in NSCLC

Wyeth to initiate Phase II study of Neratinib in Breast cancer

Wyeth are soon to initiate a Phase II study of Neratinib in Solid Tumors and Breast cancer

Novatis EGFR/VEGFR inhibitor AEE788 preclinical data

Novartis have published preclinical information on its EGFR/VEGFR inhibitor AEE788  in the New England Journal of Medicine. IC50s were found to be 2nM for EGFR/VEGF receptor tyrosine kinases and 6 nM for ErbB2

Tykerb receives conditional EU marketing approval for HER2 breast cancer

GlaxoSmithKline have received a conditional marketing authorisation from the european autorities for lapatinib (Tyverb, Tykerb). The approval is for the use of lapatinib in advanced or metastatic HER2 positive breast cancer in combination with capecitabine.

Phase II data on lapatinib (Tykerb) presented at ASCO

Data presented at ASCO highlight recent findings with lapatinib including:
- Phase II data on Lapatinib in combination with pazopanib demonstrates activity in first-line HER2 positive breast cancer
- Phase II data on Lapatinib in combination with bevacizumab shows efficacy in recurrent metastatic HER2 positive breast cancer
– Monotherapy for relapsed inflammatory breast cancer shows [...]

Phase I dose escalation trial of Lapatinib in combination with trastuzumab

Phase I results show that combining 1000 mg lapatinib and weekly trastuzumab is well tolerated